Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:


The clinical and economic burden of NAFLD: time to turn the tide

In a new study, Younossi et al. poignantly depict the daunting and enormous prevalence of NAFLD and its associated clinical and economic burden in the USA and four countries in Europe. The astronomical health-care costs will increase as the prevalence of NAFLD increases. All stakeholders are called to action.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout


  1. Younossi, Z. M. et al. The economic and clinical burden of non-alcoholic fatty liver disease (NAFLD) in the United States and Europe. Hepatology (2016).

  2. Rinella, M. E. et al. Practice patterns in NAFLD and NASH: real life differs from published guidelines. Therap. Adv. Gastroenterol. 9, 4–12 (2016).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Said, A., Gagovic, V., Malecki, K., Givens, M. L. & Nieto, F. J. Primary care practitioners survey of non-alcoholic fatty liver disease. Ann. Hepatol. 12, 758–765 (2013).

    Article  PubMed  Google Scholar 

  4. Wong, V. W. et al. Community-based lifestyle modification programme for non-alcoholic fatty liver disease: a randomized controlled trial. J. Hepatol. 59, 536–542 (2013).

    Article  PubMed  Google Scholar 

  5. Vilar-Gomez, E. et al. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology 149, 367–378.e5 (2015).

    Article  PubMed  Google Scholar 

  6. Abdelmalek, M. F. et al. Increased fructose consumption is associated with fibrosis severity in patients with nonalcoholic fatty liver disease. Hepatology 51, 1961–1971 (2010).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Sun, W. et al. Comparison of FIB-4 index, NAFLD fibrosis score and BARD score for prediction of advanced fibrosis in adult patients with non-alcoholic fatty liver disease: a meta-analysis study. Hepatol. Res. 46, 862–870 (2016).

    Article  CAS  PubMed  Google Scholar 

  8. Sanyal, A. J. et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N. Engl. J. Med. 362, 1675–1685 (2010).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Armstrong, M. J. et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet 387, 679–690 (2016).

    Article  CAS  PubMed  Google Scholar 

  10. Kargiotis, K. et al. Resolution of non-alcoholic steatohepatitis by rosuvastatin monotherapy in patients with metabolic syndrome. World J. Gastroenterol. 21, 7860–7868 (2015).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations


Corresponding author

Correspondence to Manal F. Abdelmalek.

Ethics declarations

Competing interests

The author declares no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Abdelmalek, M. The clinical and economic burden of NAFLD: time to turn the tide. Nat Rev Gastroenterol Hepatol 13, 685–686 (2016).

Download citation

  • Published:

  • Issue Date:

  • DOI:

This article is cited by


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing